{"id":"intradermal-influenza-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site erythema"},{"rate":null,"effect":"Injection site induration"},{"rate":null,"effect":"Injection site pruritus"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Intradermal administration targets the dermis layer of skin, which is rich in dendritic cells and other antigen-presenting cells, potentially generating stronger and broader cellular and humoral immune responses compared to intramuscular vaccination. This route may improve immunogenicity and potentially reduce the antigen dose required while maintaining or enhancing protective efficacy against influenza infection.","oneSentence":"An intradermal influenza vaccine that delivers the vaccine antigen into the dermis to enhance immune response through activation of skin-resident immune cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:39.152Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Influenza prevention in adults"}]},"trialDetails":[{"nctId":"NCT03396575","phase":"PHASE1","title":"Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)","status":"TERMINATED","sponsor":"University of Florida","startDate":"2018-07-17","conditions":"Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma","enrollment":11},{"nctId":"NCT06067555","phase":"EARLY_PHASE1","title":"Intradermal Influenza Vaccination","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-01-24","conditions":"Vaccine Reaction","enrollment":249},{"nctId":"NCT01538940","phase":"PHASE4","title":"Immunogenicity of Influenza Vaccines in HIV-infected Persons in Thailand","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2011-11-01","conditions":"Influenza","enrollment":415},{"nctId":"NCT00386542","phase":"PHASE1, PHASE2","title":"Needle-free Jet Injection of Reduced-dose, Intradermal, Influenza Vaccine in >= 6 to < 24-month-old Children","status":"COMPLETED","sponsor":"Pedro Moro","startDate":"2006-10","conditions":"Influenza","enrollment":450},{"nctId":"NCT06046092","phase":"PHASE1","title":"H7HLAII DNA Influenza Vaccine","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2023-07-15","conditions":"Influenza A, Pandemic Influenza","enrollment":27},{"nctId":"NCT01676402","phase":"PHASE1","title":"Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-08","conditions":"Influenza","enrollment":316},{"nctId":"NCT04143451","phase":"PHASE3","title":"Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2019-10-23","conditions":"Influenza","enrollment":4000},{"nctId":"NCT03448705","phase":"PHASE1","title":"Safety of 4Fluart ID Suspension for Injection in Adult Subjects","status":"COMPLETED","sponsor":"Fluart Innovative Vaccine Ltd, Hungary","startDate":"2018-01-31","conditions":"Human Influenza","enrollment":36},{"nctId":"NCT02554409","phase":"","title":"Sanofi Pasteur Quadrivalent Intradermal Influenza Vaccine Pregnancy Registry","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-10-13","conditions":"Pregnancy, Influenza","enrollment":87},{"nctId":"NCT01215669","phase":"PHASE4","title":"Study of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-10","conditions":"Influenza","enrollment":240},{"nctId":"NCT02141581","phase":"PHASE4","title":"Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2011-08","conditions":"Influenza","enrollment":86},{"nctId":"NCT01202552","phase":"NA","title":"Two-site Intradermal Influenza Vaccination in Elderly","status":"COMPLETED","sponsor":"Queen Saovabha Memorial Institute","startDate":"2010-10","conditions":"Influenza","enrollment":180},{"nctId":"NCT00554333","phase":"PHASE3","title":"Comparative Study of Immunogenicity and Safety of Flu-ID Vaccine Versus Flu-IM Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-10","conditions":"Influenza","enrollment":795},{"nctId":"NCT02988739","phase":"PHASE1","title":"Comparison of Laser Assisted Epidermal to Intradermal Administration of Seasonal Influenza Vaccine","status":"COMPLETED","sponsor":"Pantec Biosolutions AG","startDate":"2017-02-22","conditions":"Influenza in Human","enrollment":20},{"nctId":"NCT02960815","phase":"PHASE2","title":"Imiquimod and Influenza Vaccine for Immunocompromised Patients","status":"COMPLETED","sponsor":"University of Lausanne Hospitals","startDate":"2016-11","conditions":"Influenza Vaccine","enrollment":70},{"nctId":"NCT01403155","phase":"PHASE1","title":"A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001","status":"COMPLETED","sponsor":"Inovio Pharmaceuticals","startDate":"2011-05","conditions":"Healthy","enrollment":22},{"nctId":"NCT01665807","phase":"PHASE4","title":"A Time-motion Study Comparing Self- to Nurse-vaccination With Influenza Vaccine","status":"COMPLETED","sponsor":"Brenda Coleman","startDate":"2012-09","conditions":"Influenza, Vaccination Site Reactions (HT)","enrollment":868},{"nctId":"NCT01737710","phase":"NA","title":"Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-10","conditions":"Dermatitis, Atopic","enrollment":368},{"nctId":"NCT01518478","phase":"EARLY_PHASE1","title":"Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Pilot","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-11","conditions":"Atopic Dermatitis","enrollment":40},{"nctId":"NCT02563093","phase":"PHASE4","title":"Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-09","conditions":"Influenza","enrollment":208},{"nctId":"NCT00551031","phase":"PHASE2","title":"Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-10","conditions":"Influenza, Myxovirus Infection","enrollment":2098},{"nctId":"NCT00848848","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older","status":"COMPLETED","sponsor":"Seqirus","startDate":"2008-10","conditions":"Influenza","enrollment":450},{"nctId":"NCT00623181","phase":"PHASE2","title":"Study to Determine a Preference for Fluzone Vaccine Given Intradermally (ID) and Intramuscularly (IM) in Healthy Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-01","conditions":"Influenza","enrollment":110},{"nctId":"NCT01011049","phase":"PHASE2","title":"Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-09","conditions":"Influenza","enrollment":1250},{"nctId":"NCT00772109","phase":"PHASE3","title":"Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-10","conditions":"Orthomyxoviridae Infection, Influenza, Myxovirus Infection","enrollment":4292},{"nctId":"NCT02101749","phase":"PHASE4","title":"Immune Response of Intradermal and Intramuscular Preparations of Inactive Seasonal Influenza Vaccine in Older Age Group.","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2013-11","conditions":"Influenza, Human","enrollment":221},{"nctId":"NCT01403376","phase":"PHASE2","title":"Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-09","conditions":"Multiple Sclerosis","enrollment":128},{"nctId":"NCT02258334","phase":"PHASE4","title":"Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2014-10","conditions":"Influenza","enrollment":208},{"nctId":"NCT01138397","phase":"PHASE3","title":"Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intradermal Route)","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-06","conditions":"Influenza","enrollment":129},{"nctId":"NCT00776438","phase":"PHASE2","title":"Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-09","conditions":"Influenza, Orthomyxovirus Infections, Myxovirus Infection","enrollment":160},{"nctId":"NCT00760175","phase":"NA","title":"Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Lung Transplant Recipients","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2008-10","conditions":"Influenza Virus, Influenza Vaccine","enrollment":85},{"nctId":"NCT01180699","phase":"NA","title":"Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Solid Organ Transplant Recipients","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2010-10","conditions":"Influenza Vaccine","enrollment":229},{"nctId":"NCT01712984","phase":"PHASE3","title":"Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2012-10","conditions":"Influenza","enrollment":3360},{"nctId":"NCT01587131","phase":"PHASE1","title":"DNA-based Influenza Vaccine in the Elderly","status":"COMPLETED","sponsor":"University of Manitoba","startDate":"2012-06","conditions":"Influenza, Human, Orthomyxoviridae Infections, RNA Virus Infections","enrollment":50},{"nctId":"NCT01368796","phase":"PHASE4","title":"Comparison of 4 Influenza Vaccines in Seniors","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-07","conditions":"Influenza Vaccine","enrollment":953},{"nctId":"NCT02398097","phase":"PHASE4","title":"Conventional Vaccine and Intradermal Vaccine Among HIV-infected Young Subjects","status":"COMPLETED","sponsor":"Korea University Guro Hospital","startDate":"2011-11","conditions":"Human Influenza","enrollment":88},{"nctId":"NCT00893945","phase":"PHASE1","title":"Autologous Dendritic Cells Pulsed With Autologous Apoptotic Tumor Cells Administered to Patients With Brain Tumors","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"2007-06","conditions":"Brain Tumors","enrollment":19},{"nctId":"NCT00170547","phase":"PHASE2","title":"Comparison of Delivery Routes of Flu Vaccine in Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-09","conditions":"Influenza","enrollment":1597},{"nctId":"NCT02103023","phase":"PHASE3","title":"Intradermal Influenza Vaccine in the Young","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2014-03","conditions":"Influenza Viral Infections","enrollment":160},{"nctId":"NCT01946438","phase":"PHASE4","title":"Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-09","conditions":"Influenza","enrollment":208},{"nctId":"NCT01405885","phase":"PHASE1","title":"A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus","status":"COMPLETED","sponsor":"Inovio Pharmaceuticals","startDate":"2011-05","conditions":"Healthy","enrollment":116},{"nctId":"NCT00945438","phase":"PHASE2","title":"Study of the Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation (Intradermal Route)","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-05","conditions":"Influenza","enrollment":131},{"nctId":"NCT00606359","phase":"PHASE2","title":"Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-11","conditions":"Influenza, Orthomyxoviridae Infections","enrollment":62},{"nctId":"NCT00703651","phase":"PHASE2","title":"Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2003-09","conditions":"Influenza, Orthomyxoviridae Infection, Myxovirus Infection","enrollment":1150},{"nctId":"NCT00775450","phase":"PHASE2","title":"Influenza Vaccine Revaccination in Ambulatory Elderly Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-10","conditions":"Influenza, Orthomyxovirus Infection, Myxovirus Infection","enrollment":807},{"nctId":"NCT01049490","phase":"NA","title":"Dose Sparing Intradermal S-OIV H1N1 Influenza Vaccination Device","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2010-01","conditions":"Influenza Infection","enrollment":262},{"nctId":"NCT01508884","phase":"NA","title":"Intradermal Trivalent Influenza Vaccine With Imiquimod","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2012-01","conditions":"Chronic Illness","enrollment":93},{"nctId":"NCT01691339","phase":"PHASE4","title":"Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2012-09","conditions":"Influenza","enrollment":200},{"nctId":"NCT01967368","phase":"PHASE4","title":"Safety and Efficacy of Intradermal Trivalent Influenza Vaccination in Institutionalized Older Adults","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2013-10","conditions":"Influenza, Human","enrollment":100},{"nctId":"NCT01737580","phase":"PHASE1","title":"Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) Agonists","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2013-04","conditions":"Influenza Vaccination in Seniors","enrollment":59},{"nctId":"NCT01707602","phase":"PHASE1, PHASE2","title":"Routes of Immunization and Flu Immune Responses","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-10","conditions":"Influenza","enrollment":60},{"nctId":"NCT00253734","phase":"PHASE2","title":"Immunogenicity and Safety of Different Doses of Fluzone® Influenza","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-11","conditions":"Influenza","enrollment":217},{"nctId":"NCT00310206","phase":"PHASE1","title":"H5N1 Vaccine Intramuscular Versus Intradermal in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-07","conditions":"Influenza","enrollment":100},{"nctId":"NCT00439335","phase":"PHASE1, PHASE2","title":"Higher Dose Intradermal H5 Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-03","conditions":"Influenza","enrollment":227},{"nctId":"NCT00942071","phase":"PHASE1","title":"A Study to Assess the Safety and Immunogenicity of a New Influenza Vaccine Candidate MVA-NP+M1 in Healthy Adults","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2008-08","conditions":"Influenza","enrollment":58},{"nctId":"NCT01716130","phase":"","title":"Acceptability of Fluzone Intradermal Vaccine to Patients and Vaccine Administrators","status":"COMPLETED","sponsor":"Touro University, California","startDate":"2011-10","conditions":"Patient Response to Fluzone ID Vaccine","enrollment":249},{"nctId":"NCT00504231","phase":"PHASE2","title":"Intradermal Influenza Vaccine Study in Elders","status":"COMPLETED","sponsor":"PATH","startDate":"2007-09","conditions":"Influenza","enrollment":257},{"nctId":"NCT01582633","phase":"PHASE2, PHASE3","title":"Assessment of Needle-free Disposable-syringe Jet Injector (DSJI) ID Dose-sparing of Pandemic A H1N1 Influenza Vaccine","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2012-07","conditions":"Influenza","enrollment":300},{"nctId":"NCT00388583","phase":"PHASE2","title":"Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-09","conditions":"Orthomyxoviridae Infection, Influenza, Myxovirus Infection","enrollment":817},{"nctId":"NCT00391391","phase":"PHASE2","title":"Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-10","conditions":"Orthomyxoviridae Infection, Influenza, Myxovirus Infection","enrollment":520},{"nctId":"NCT01224613","phase":"PHASE4","title":"Study to Compare Self-administered and Nurse-administered Intradermal Influenza Vaccine","status":"COMPLETED","sponsor":"Dalhousie University","startDate":"2010-11","conditions":"Influenza","enrollment":276},{"nctId":"NCT01304563","phase":"NA","title":"2010/2011 Trivalent Influenza Vaccination","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2010-11","conditions":"Influenza","enrollment":240},{"nctId":"NCT01273974","phase":"PHASE2, PHASE3","title":"The Immunogenicity of Intradermal Influenza Vaccination in Hemodialysis Patients","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2009-10","conditions":"Hemodialysis Patients","enrollment":130},{"nctId":"NCT01039623","phase":"NA","title":"Assessment of Safety and Immunogenicity of Intradermal Unadjuvanted Portion of Pandemrix® Via a Microneedle Device With Intramuscular Adjuvanted Pandemrix® as Reference","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2010-01","conditions":"Healthy","enrollment":200},{"nctId":"NCT00814229","phase":"PHASE1","title":"Safety and Immunogenicity of Influenza H9 Vaccine in Humans","status":"COMPLETED","sponsor":"University Hospitals, Leicester","startDate":"2007-08","conditions":"Influenza","enrollment":353},{"nctId":"NCT00402805","phase":"PHASE4","title":"Improving the Humoral Response to Influenza Vaccine in Lung Transplant Recipients by an Intradermal Strategy","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2006-10","conditions":"Lung Transplantation, Influenza Vaccines","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":37,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Intradermal influenza vaccine","genericName":"Intradermal influenza vaccine","companyName":"The University of Hong Kong","companyId":"the-university-of-hong-kong","modality":"Biologic","firstApprovalDate":"","aiSummary":"An intradermal influenza vaccine that delivers the vaccine antigen into the dermis to enhance immune response through activation of skin-resident immune cells. Used for Influenza prevention in adults.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}